The risk of osteoporosis in patients with asthma.

IF 1.8 Q3 RESPIRATORY SYSTEM

European Clinical Respiratory Journal Pub Date : 2020-05-19 eCollection Date: 2020-01-01 DOI:10.1080/20018525.2020.1763612

Indumathi Kumarathas, Torben Harsløf, Charlotte Uggerhøj Andersen, Bente Langdahl, Ole Hilberg, Leif Bjermer, Anders Løkke

{"title":"The risk of osteoporosis in patients with asthma.","authors":"Indumathi Kumarathas, Torben Harsløf, Charlotte Uggerhøj Andersen, Bente Langdahl, Ole Hilberg, Leif Bjermer, Anders Løkke","doi":"10.1080/20018525.2020.1763612","DOIUrl":null,"url":null,"abstract":"<p><p>It is well-known that use of continuous systemic corticosteroids (SG) affects bone metabolism, bone mineral density (BMD), and ultimately increases the risk of osteoporosis. In patients with asthma, on the other hand, the effects of long-term high-dose inhaled corticosteroids (ICS) on BMD and risk of osteoporotic fractures is controversial. The reasons for this inconsistency could be explained by the fact that only few long-term studies investigating the effect of ICS in patients with asthma exist. The studies are characterized by different study designs and duration of ICS exposure, small study populations, and differences between the used ICS. The aim of this article is to unravel which factors, if any, that contribute to an increased risk of osteoporosis in patients with asthma and to summarize the evidence regarding adverse effects of ICS on bone metabolism, BMD and osteoporotic fractures in patients with asthma.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2020-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20018525.2020.1763612","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Clinical Respiratory Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20018525.2020.1763612","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 11

Abstract

It is well-known that use of continuous systemic corticosteroids (SG) affects bone metabolism, bone mineral density (BMD), and ultimately increases the risk of osteoporosis. In patients with asthma, on the other hand, the effects of long-term high-dose inhaled corticosteroids (ICS) on BMD and risk of osteoporotic fractures is controversial. The reasons for this inconsistency could be explained by the fact that only few long-term studies investigating the effect of ICS in patients with asthma exist. The studies are characterized by different study designs and duration of ICS exposure, small study populations, and differences between the used ICS. The aim of this article is to unravel which factors, if any, that contribute to an increased risk of osteoporosis in patients with asthma and to summarize the evidence regarding adverse effects of ICS on bone metabolism, BMD and osteoporotic fractures in patients with asthma.

Abstract Image

查看原文本刊更多论文

哮喘患者骨质疏松的风险。

众所周知，持续使用全身皮质类固醇(SG)会影响骨代谢、骨矿物质密度(BMD)，并最终增加骨质疏松症的风险。另一方面，在哮喘患者中，长期大剂量吸入皮质类固醇(ICS)对骨密度和骨质疏松性骨折风险的影响存在争议。这种不一致的原因可以用这样一个事实来解释:只有很少的长期研究调查了ICS对哮喘患者的影响。这些研究的特点是研究设计和ICS暴露时间不同，研究人群较小，使用的ICS之间存在差异。本文的目的是揭示哪些因素(如果有的话)导致哮喘患者骨质疏松症的风险增加，并总结有关ICS对哮喘患者骨代谢、骨密度和骨质疏松性骨折的不良影响的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊